Valneva SE (VALN): Financial results for H1 2026
Valneva SE (VALN) furnished an SEC Form 6-K — earnings release. VALNEVA SE Îlot Saint-Joseph, Bureaux Convergence, Bât. A, 12 ter Quai Perrache 69002 Lyon, France Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates • Total product sales of €64.0 million o In-line with expectations; full-year guidance of €135 -150 m
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on revenue decline, increased loss, and cash position, informing short‑term trading decisions.
Market read
Primary earnings disclosure for a listed biotech; new numbers may trigger price movement.
What to watch
Potential upside from upcoming regulatory decisions on the Lyme vaccine and the sale of the Nantes site.
Valneva reported lower H1 2026 product sales and a wider IFRS net loss, while reaffirming 2026 product-sales and total-revenue guidance and ending June with €121.5 million of cash and cash equivalents.
Product sales declined to €64.0 million from €91.0 million, gross profit fell to €6.3 million, and net loss widened to €63.3 million. The company reaffirmed its 2026 sales and revenue guidance, completed a restructuring program, and increased cash and cash equivalents to €121.5 million following the reserved offering.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenuesother | €65.8 million | – | – |
| Product salesother | €64.0 million | – | – |
| Other revenues, including revenues from collaborations, licensing and servicesother | €1.8 million | – | – |
| Costs of goods and services soldother | €59.5 million | – | – |
| Gross profitother | €6.3 million | – | – |
| Gross profit / total revenuesother | 9.6% | – | – |
| Product-level gross profit before unallocated costsother | €14.7 million | – | – |
| Product-level gross margin before unallocated costsother | 23.0% | – | – |
| Unallocated manufacturing costsother | €9.4 million | – | – |
| Research and development expensesother | €30.2 million | – | – |
| Marketing and distribution expensesother | €13.5 million | – | – |
| General and administrative expensesother | €15.4 million | – | – |
| Other income, net of other expensesother | €2.9 million | – | – |
| Operating lossother | €49.9 million | – | – |
| Net finance expenseother | €13.1 million | – | – |
| Net lossother | €63.3 million | – | – |
| Adjusted EBITDA lossnon-GAAP | €40.1 million | – | – |
| Cash and cash equivalentsother | €121.5 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| IXIARO® / JESPECT®The year-over-year comparison primarily reflects the transition to a new distributor in Germany in January 2026 and product-sales phasing, notably the timing of deliveries to the U.S. DoD. | €44.0 million | – | – |
| DUKORAL®The prior-year period benefited from one-time sales associated with vaccine doses supplied to Mayotte during a cholera outbreak; H1 2026 was affected by the German distributor transition and adverse travel conditions. | €14.7 million | – | – |
| IXCHIQ®Sales included initial shipments of vaccine drug substance to Instituto Butantan, while the prior-year period benefited from U.S. sales and 40,000 doses supplied to La Réunion during a chikungunya outbreak. | €4.4 million | – | – |
| Third-party product salesSales decreased following the expiration of the Company’s main distribution agreement in 2025 and the planned wind-down of third-party distribution activities. | €1.0 million | – | down €10.5 million, or 91.6% |
2026 outlook
- Revenue€145 million to €160 million
- NoteExpected product sales of €135 million to €150 million
- NoteProduct gross margins are expected to improve in the second half of the year following one-off effects in the first half of 2026.
- NoteThe sale of the Nantes site is expected to close in September 2026.
- NoteRegulatory decisions for LB6V are expected in the next twelve months.
- NoteResults from the two S4V2 Phase 2 studies are expected in the third quarter of 2026.
What drove it
- The planned discontinuation of the majority of third-party sales reduced revenue.
- Product sales reflected expected phasing, including the timing of IXIARO® shipments to the U.S. DoD and the distribution transition in Germany.
- H1 2025 included non-recurring outbreak-related DUKORAL® and IXCHIQ® sales that did not repeat in 2026.
- IXCHIQ® gross margin was affected by €9.7 million of one-time cancellation fees related to external manufacturing commitments and a €4.5 million non-cash impairment of excess inventory.
- R&D expenses declined following reprioritization and rescheduling of R&D activities.
- Marketing and distribution expenses fell because of lower IXCHIQ® advertising and promotional spending and reduced personnel, warehousing and distribution costs.
- G&A expenses declined on lower personnel costs and savings in advisory and professional services.
Concerns
- Gross profit declined to €6.3 million as lower sales and manufacturing volumes combined with adverse IXCHIQ® inventory provisions, third-party manufacturing and supply-contract termination costs, and higher idle manufacturing costs.
- IXCHIQ® gross margin was negative in H1 2026, and about 50% of the operating loss was generated by IXCHIQ®.
- Net finance expense increased to €13.1 million, including a foreign currency loss of €3.9 million, compared with a foreign currency gain of €7.8 million in H1 2025.
- The company cited the continued adverse impact of the geopolitical environment on travel.
- The H1 2026 restructuring program resulted in €3.2 million of expenses across affected functions.
What to watch
- Additional IXIARO® deliveries to the U.S. DoD during the remainder of 2026, including under a new contract expected in the third quarter.
- Whether product gross margins improve in the second half of 2026 following H1 one-off effects.
- Closing of the Nantes site sale expected in September 2026.
- Regulatory decisions for LB6V expected in the next twelve months.
- Results from the S4V2 Phase 2 infant safety and immunogenicity trial and Phase 2b Human Challenge trial expected in the third quarter of 2026.
- Valneva’s determination of next steps for S4V2, including whether to assume responsibility for late-stage clinical development, based on the study outcomes and future R&D strategy.
Balance sheet and cash flow
- Cash and cash equivalents were €121.5 million as at June 30, 2026, compared to €109.7 million at December 31, 2025.
- Net cash used in operating activities amounted to €13.7 million in the first half of 2026 compared to €10.9 million in the same period of 2025.
- Cash inflows from investing activities amounted to €0.6 million in the first half of 2026 compared to cash outflows of €1.6 million in the same period of 2025.
- Net cash generated by financing activities amounted to €24.5 million in the first half of 2026 compared to a net cash inflow of €9.3 million in the same period in 2025.
- Cash generated during the first half of 2026 included net proceeds of €34.3 million from a capital raise completed in the second quarter of 2026.
- Interest payments amounted to €8.9 million in the first six months of 2026 and €9.5 million in the same period of the prior year.
- The reserved offering completed in the second quarter of 2026 generated €37 million in gross proceeds.
- The Company agreed to sell its Nantes site in France for €6.2 million.
Analysis
Valneva’s H1 2026 commercial performance declined from the prior-year period. Total revenues were €65.8 million versus €97.6 million, and product sales were €64.0 million versus €91.0 million. The company attributed the decline to the planned wind-down of third-party distribution, sales phasing, the German distributor transition, timing of IXIARO® deliveries to the U.S. DoD, and outbreak-related DUKORAL® and IXCHIQ® sales recorded in H1 2025 that did not repeat.
IXIARO® / JESPECT® remained the largest commercial product at €44.0 million, followed by DUKORAL® at €14.7 million and IXCHIQ® at €4.4 million. Third-party product sales were €1.0 million, down €10.5 million, or 91.6%. The revenue mix was accompanied by substantially weaker profitability: total gross profit was €6.3 million and gross profit as a percentage of total revenues was 9.6%, versus €50.4 million and 51.7% in H1 2025. Product-level gross margin before unallocated costs was 23.0%, compared with 59.8%.
IXCHIQ® was the principal profitability pressure point. Its gross margin was negative, reflecting €9.7 million of external-manufacturing cancellation fees and a €4.5 million non-cash impairment of excess inventory after lower-than-anticipated sales. Higher idle manufacturing costs also weighed on results. Operating loss widened to €49.9 million and net loss widened to €63.3 million, while adjusted EBITDA loss increased to €40.1 million. Reduced R&D, marketing and distribution, and G&A expenses partly offset the gross-profit deterioration, reflecting reprioritization and restructuring actions.
Liquidity improved despite operating cash use. Cash and cash equivalents were €121.5 million at June 30, 2026, compared with €109.7 million at December 31, 2025. Net cash used in operating activities was €13.7 million, while financing activities generated €24.5 million, including €34.3 million in net proceeds from the second-quarter capital raise. Valneva reaffirmed 2026 product-sales guidance of €135 million to €150 million and total-revenue guidance of €145 million to €160 million, while stating that product gross margins are expected to improve in the second half.
The near-term operating milestones are additional IXIARO® DoD deliveries, the expected September 2026 closing of the Nantes site sale, S4V2 Phase 2 data in the third quarter of 2026, and LB6V regulatory decisions expected in the next twelve months. Management’s restructuring and reduced expense base are central to its stated effort to reduce cash burn, while the recovery in second-half gross margins and commercial execution across the travel-vaccine portfolio remain important reported objectives.
Management, verbatim
Our focus over the past few months, following the Lyme VALOR results has been to restructure and refocus our operations. The successful financing completed in April has enabled us to build and maintain a strong cash position, allowing us to prioritize resources on our core business and key strategic priorities while preserving the flexibility to accelerate growth should the Lyme program progress successfully toward licensure and commercialization.
Peter Bühler, Chief Financial Officer
Not in the filing
stated, not guessed- EPS, including IFRS and adjusted EPS
- Debt balance
- Free cash flow
- Dividend information
- Share repurchase information
- Tax rate and tax-rate guidance
- Quantified operating-expense guidance
- Quarter-over-quarter comparisons
- Prior outlook for comparison
- Total 2026 R&D investment guidance
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Valneva SE, a specialty vaccine developer listed on Nasdaq, released its half‑year 2026 financials via a Form 6‑K filing.
Ticker impact
Valneva SE filed a Form 6‑K reporting H1 2026 results, revealing €65.8 M revenue, €63.3 M net loss and reaffirmed 2026 guidance.
Potential modest decline ahead of market reaction, with upside capped unless guidance is upgraded.
Revenue down YoY and larger loss are material, but cash position and guidance remain stable, suggesting limited long‑term impact.
Market effects
Biotech/ vaccine sector may see heightened scrutiny on late‑stage Lyme vaccine candidates.
European biotech investors may reassess exposure to companies with similar cash‑burn profiles.
Limited; primarily affects Valneva and peers in specialty vaccine space.
Counterpoint
The cash buffer and reaffirmed guidance could support a bounce if market overreacts to the loss.
Key entities
- companyValneva SE
Specialty vaccine developer (NASDAQ: VALN).
- partnerPfizer
Collaborator on Lyme disease vaccine candidate.
